Gain-of-function mutations in PCSK9 lead to high levels of low-density lipoproteins in the blood (hypercholesterolemia) because they promote the degradation of LDL receptors, whereas loss-of-function mutations markedly reduce the levels of low-density lipoproteins. This evidence concerns the gene PCSK9 and Hypercholesterolemia.